Vyvanse: Impacts During Pregnancy, Breastfeeding, and Beyond
Warning: Vyvanse Use During Pregnancy and Breastfeeding May Cause Harm
Vyvanse, a brand-name drug used for Attention Deficit Hyperactivity Disorder (ADHD) and binge eating disorder, carries potential risks during pregnancy and breastfeeding. The drug contains the active ingredient lisdexamfetamine dimesylate, which is an amphetamine and stimulant drug.
Pregnancy Risks
Vyvanse is classified as FDA pregnancy category C, meaning animal studies have shown adverse fetal effects but there are no well-controlled human studies. Human data are limited, but some case studies have linked amphetamine use to premature delivery and low birth weight. No clear increase in congenital abnormalities has been established. Animal studies have shown some evidence of fetal damage, but its significance in humans remains uncertain.
The drug may stimulate contractions in the womb, potentially causing premature birth. It may also cause problems such as narrowing of blood vessels, restriction of blood supply to the placenta and fetus, and serious cardiovascular problems, including increased blood pressure and fast heartbeat.
Breastfeeding Risks
Due to the potential for Vyvanse and its metabolites to pass into breast milk, the drug is not recommended for breastfeeding mothers. It may cause serious side effects in a child who is breastfed, including feeding problems, slowed growth, and withdrawal symptoms such as irritability, difficulty feeding, agitation, or excessive drowsiness.
Additional Considerations
Due to risks of abuse and cardiovascular side effects, Vyvanse is contraindicated in pregnancy unless the benefits justify the risks. It should only be used under strict medical supervision. If pregnant or planning to become pregnant, discuss the risks and benefits of taking Vyvanse with a doctor.
If you're breastfeeding or planning to breastfeed, talk with your doctor about alternative medications. It is not known whether Vyvanse affects the way your body makes breast milk.
In summary, Vyvanse use during pregnancy and breastfeeding is associated with potential fetal harm, neonatal withdrawal symptoms, and is generally advised against without compelling medical need and physician oversight.
[1] Mayo Clinic. (2021). Vyvanse. Retrieved from https://www.mayoclinic.org/drugs-supplements/vyvanse/description/drg-20074723
[2] Drugs.com. (2021). Vyvanse. Retrieved from https://www.drugs.com/vyvanse.html
[3] U.S. Food and Drug Administration. (2021). Pregnancy and breastfeeding. Retrieved from https://www.fda.gov/drugs/resources-pregnant-women/pregnancy-and-breastfeeding
[4] National Institute on Drug Abuse. (2021). Vyvanse. Retrieved from https://www.drugabuse.gov/publications/drugfacts/vyvanse
- Pfizer's Vyvanse, a drug used for ADHD and binge eating disorder, is classified as FDA pregnancy category C, indicating potential risks during pregnancy, with limited human data linking amphetamine use to premature delivery and low birth weight.
- Despite science advising caution, Vyvanse is blocked from being recommended for breastfeeding mothers due to the potential for its metabolites to pass into breast milk, causing possible side effects in nursing infants.
- As mental-health therapies and treatments evolve, it's crucial to consider alternatives to Vyvanse during pregnancy and breastfeeding, given the health-and-wellness concerns associated with its use during these critical periods.
- Before making a decision, it's essential to consult with healthcare providers about the effects of Vyvanse on nutrition and breast milk production, as well as the potential risks and benefits during pregnancy and breastfeeding.
